Literature DB >> 9559466

Prompt re-treatment after photorefractive keratectomy.

M Pop1.   

Abstract

PURPOSE: To study eyes that received a photorefractive keratectomy (PRK) retreatment 1 to 4 months after the first treatment and describe refractive stability and complications.
SETTING: Michael Pop CLinics, Montreal, Canada.
METHODS: Twenty-six eyes of 20 patients were re-treated for undercorrection and, regression with or without haze. Postoperative refractions were performed at 1, 2, 3, and 6 months. Haze was evaluated on a scale of 0 to 4.
RESULTS: Ninety percent of the 21 eyes followed for 6 months after re-treatment achieved an uncorrected visual acuity of 20/40. At 6 months, 67 and 95% of eyes were within +/- 0.50 diopter (D) and +/- 1.00 D, respectively. Regression between 1 and 6 months after re-treatment was 0.71 D, which represented less than one half that observed after the initial treatment. Six months after re-treatment, haze decreased by half, and no eye had haze above 1. Best corrected visual acuity (BCVA) before treatment was well correlated with values 6 months after re-treatment (P < .001). At 6 months, 1 eye lost two lines of BCVA but had an acuity of 20/30 and 2 eyes lost one line of BCVA.
CONCLUSION: Prompt re-treatment after PRK for myopia allowed management of undercorrections and regressions with low morbidity and high refractive stability. By re-treating promptly, no additional complications were created and patients avoided long periods of unsatisfactory vision.

Entities:  

Mesh:

Year:  1998        PMID: 9559466     DOI: 10.1016/s0886-3350(98)80318-0

Source DB:  PubMed          Journal:  J Cataract Refract Surg        ISSN: 0886-3350            Impact factor:   3.351


  2 in total

1.  Recent advances in refractive surgery.

Authors:  E Y Yu; W B Jackson
Journal:  CMAJ       Date:  1999-05-04       Impact factor: 8.262

2.  Predictability and stability of laser-assisted subepithelial keratectomy with mitomycin C for the correction of high myopia.

Authors:  Lawrence P L Iu; Michelle C Y Fan; Ivan N Chen; Jimmy S M Lai
Journal:  Medicine (Baltimore)       Date:  2017-06       Impact factor: 1.889

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.